𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia

✍ Scribed by Chris L. Pashos; Kay Larholt; Kimberly A. Fraser; R. Scott McKenzie; Mekré Senbetta; Catherine Tak Piech

Publisher
Springer-Verlag
Year
2011
Tongue
English
Weight
211 KB
Volume
20
Category
Article
ISSN
0941-4355

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Usage of erythropoiesis-stimulating agen
Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia
✍ Alessandra Ferrajoli; Aman U. Buzdar; Yvette DeJesus; Lee Cheng; Laura B. Michau 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 627 KB

## Abstract ## BACKGROUND: In 2007, the US Food and Drug Administration (FDA) issued regulatory alerts for use of erythropoiesis‐stimulating agents (ESAs) in cancer patients with anemia after clinical trials and meta‐analysis data found that high ESA doses were associated with adverse outcomes in

Recombinant erythropoietin in acute chem
Recombinant erythropoietin in acute chemotherapy-induced anemia of children with cancer
✍ Beck, Maja Nenadov ;Beck, Daniel 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB

## Abstract Chemotherapy‐induced anemia in children with cancer is usually of acute onset. To investigate an alternate treatment to transfusion (Tx), we undertook a phase I‐II clinical trial of daily administrations of recombinant erythropoietin (rHuEPO). Patients with a hemoglobin (Hgb) value <75